Hf (IV) 复合物的抗瘤和细胞机制 (四-8-基胺) 复合物
Tiankun Zhao1, Dongyu Mei2, Jing Ma2
1School of Life Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, China; Centro de Química Estrutural and Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal..
Journal of inorganic biochemistry
|May 15, 2025
概括
新的哈夫复合物显示出强大的抗癌活性,特别是对抗肝癌细胞. [HfIV(L1)4]有效地抑制癌细胞生长,并诱导具有低毒性的亡,为西斯替代品提供了有前途的替代品.
科学领域:
- 无机化学 无机化学 有机化学
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 8-基诺林衍生物因其生物活性而闻名.
- 目前正在探索哈夫尼复合物的治疗应用.
- 开发具有提高疗效和选择性的新型抗癌药物至关重要.
研究的目的:
- 为了合成和表征新型的8-基诺林稳定型哈夫复合物.
- 评估这些复合物的体外抗癌活性与各种人类癌症细胞系相对应.
- 为了研究最强大的哈夫复合物的作用机制.
主要方法:
- 三种哈夫复合物的合成:[HfIV(oxinate) 4],[HfIV(L1) 4],[HfIV(L2) 4和[HfIV(L3) 4].
- 在体外细胞毒性测定使用Hep G2,HeLa S3和PC9癌细胞系,以及AML12非瘤源细胞.
- 机理学研究包括细胞迁移,活性氧物种 (ROS) 生成,线粒体膜潜力,细胞循环分析,亡试验和西斑分析.
主要成果:
- 所有合成的哈夫复合物都表现出良好的水性稳定性和可溶性.
- [HfIV{L1}4]和[HfIV{L3}4]对肝,宫和肺癌细胞具有强大的抑制活性,对正常细胞有低毒性.
- [HfIV(L1)4]与西斯普拉丁相比,显示出更高的疗效 (IC50 = 0.8μM对Hep G2细胞).
- 机制研究表明[HfIV(L1)4]抑制细胞迁移,诱导ROS,破坏线粒体潜能,在G2/M停止细胞循环,并通过caspase-3和Bax上调和Bcl-2下调促进细胞亡.
- 与[ZrIV{L1}4]进行比较,表明[HfIV{L1}4]主要诱导早期的亡,这是有利的.
结论:
- 合成的8-基诺林稳定复合物,特别是[HfIV (L1) 4],是有前途的新型抗癌药物.
- [HfIV(L1)4]对具有有利选择性特征的人类肝癌细胞具有显著的疗效.
- 亡途径是[HfIV (L1) 4) ]的关键作用机制.
- 这些哈夫复合物的进一步治疗开发是有必要的.
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
110
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K